Sartorius Stedim Biotech Shares Reach €228.40 Before Falling 2%
The bioprocessing specialist slipped in early afternoon trading, while the Paris Bourse was rising. It touched a technical threshold monitored for several sessions before falling back, and its valuation remains a topic for analysts.
A Resistance Touched Intraday, Then Abandoned
Sartorius Stedim Biotech shares fell 1.94% to €222.40, in an SBF 120 index up 0.56%.
The stock broke above its €228.40 resistance intraday, reaching a high of €228.80, before dropping back below it. This pullback did not take it out of its medium-term uptrend: the price remains above the 20-day moving average (a gap of 0.89%), the 50-day and the 200-day moving averages, the latter at €183.68.
Over the week, performance is virtually flat at -0.54%, while the stock retains a 23.28% gain over three months. Among the biggest decliners in the SBF 120 this Thursday, it is moving against the tide of a rising market.
Confirmed Targets and a Demanding Valuation
When it published its nine-month 2026 results on October 22, the group had confirmed its targets and said it was confident for the end of the year, with free cash flow up 58.5% over nine months. It cited strong growth in Asia/Pacific, at 10.6% at constant exchange rates, among its opportunities. It also pointed to the geopolitical situation and the growing weight of trade policy among its risks.
According to the consensus of the analysts covering the stock, the shares trade at about 44.7 times earnings for the current fiscal year and 36.7 times those of the following year. The next technical marker is the €228.40 resistance, touched today without being held.
